Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2015 ASCO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Brahmer on Impact of CheckMate-057 in NSCLC
Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer
Dr. Kari Wisinski on Palbociclib for Metastatic Breast Cancer
Oncology Conference Articles
Practical Advice for Immunotherapy Era Emerges From ASCO
For clinicians, a central message from 2015 ASCO is that a framework for managing immune-related adverse events in patients who receive these immune checkpoint agents is taking shape.
ASCO 2015: Immuno-Oncology Again Takes Center Stage
The ASCO annual meeting has retained its core purpose of providing a unique platform for oncologists to interact and exchange the latest practice-changing research.
Frontline BRAF/MEK Combo Improves Survival in Melanoma
Combination MEK/BRAF inhibition with trametinib and dabrafenib reduced the risk of death by 29% in patients with BRAF-mutant advanced melanoma.
Triplet Therapy Effective in BRAF-mutant mCRC
The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.
2015 ASCO Annual Meeting Highlights
Laura Jones recaps major findings from the 2015 ASCO Annual Meeting, including phase III findings for new treatments in melanoma, chronic lymphocytic leukemia, lung cancer, breast cancer, and multiple myeloma.
Lenvatinib Plus Everolimus Improves Survival in mRCC
The combination of lenvatinib and everolimus more than doubled progression-free survival and extended overall survival by 10.1 months compared with everolimus alone as a second-line treatment for patients with metastatic renal cell carcinoma.
Carfilzomib Tops Bortezomib in Relapsed Myeloma
Progression-free survival in relapsed myeloma doubled among patients treated with carfilzomib, rather than bortezomib, in combination with dexamethasone, a randomized trial showed.
PD-1/PD-L1 Inhibitors Safe, Effective in Advanced Ovarian Cancer
Monoclonal antibodies against PD-1 and PD-L1 have demonstrated encouraging signs of antitumor activity for patients with pretreated advanced ovarian cancer.
Trabectedin Extends PFS in Phase III Soft Tissue Sarcoma Study
Trabectedin reduced the risk of disease progression by 45% versus dacarbazine in patients with advanced soft tissue sarcoma.
Neratinib Reduces HER2+ Breast Cancer Recurrences in Phase III ExteNET Study
Treatment with neratinib immediately following adjuvant trastuzumab plus chemotherapy modestly improved invasive disease-free survival against placebo at the cost of low-grade diarrhea in almost all patients with HER2-positive early-stage breast cancer.
Largest-Ever Precision Medicine Oncology Trial Ready for Launch
A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer types aims to test the efficacy of more than 20 drugs simultaneously in an ambitious National Cancer Institute plan to further propel oncology drug discovery into the precision medicine era.
ASCO Provides Early Look at CancerLinQ Big Data Initiative
At the 2015 ASCO Annual Meeting, the much heralded CancerLinQ big data system for helping oncologists more clearly understand treatment patterns and options was offered for demonstration in advance of its rollout.
Off-Label Access to Targeted Therapies Offered Through ASCO's First-Ever Clinical Trial
Physicians will now have a new option for some patients who have run out of them, but whose tumors have a genomic variation matching a drug target that is FDA-approved for a different cancer.
Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer
In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.
Eribulin Elicits Survival Advantage in Phase III Sarcoma Study
Treatment with eribulin (Halaven) improved overall survival by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma and adipocytic sarcoma.
Survivors of Childhood Cancers Living Longer Due to Improvements in Care and Follow-up
Over the past 30 years, survivors of childhood cancers have become less likely to die of illnesses caused by their treatment, such as new malignancies or cardiac or lung disease.
Preventive Neck Lymph Node Surgery Should Become Standard of Care in Early Oral Cancer
Elective neck dissection performed at the same time patients have surgery for early-stage, node-negative, oral squamous cell cancer significantly improved overall survival and reduced the risk of death and recurrence when compared with a watchful waiting approach.
Whole Brain Radiation More Harmful Than Beneficial for Small Brain Metastases
Patients with small brain metastases from other tumor types should not routinely receive adjuvant whole brain radiation therapy (WBRT), according to a study that showed the treatment dramatically increases the incidence of cognitive decline without improving survival outcomes.
Numerous NSCLC Studies Offer Optimism for New Therapies
Novel targeted therapies against ALK, BRAF, and RET have demonstrated promising outcomes in molecularly-defined patients with non-small cell lung cancer.
Frontline Nivolumab Regimens Significantly Improve PFS Versus Ipilimumab in Melanoma
Frontline nivolumab as monotherapy and in combination with ipilimumab more than doubled progression-free survival versus ipilimumab alone in patients with advanced melanoma.
Study Disputes Lymph Node Removal Standard in Melanoma
Patients with melanoma who are found to have micrometastases after an initial positive sentinel node biopsy can safely forgo a complete lymph node dissection, thus avoiding the risk of debilitating adverse events from the surgery.
Atezolizumab Doubles OS in PD-L1-Positive NSCLC
Treatment with atezolizumab doubled overall survival compared with docetaxel in previously treated patients with PD-L1-positive squamous and non-squamous non-small cell lung cancer.
MEDI4736, Tremelimumab Combo Active in Pretreated NSCLC
An immunotherapy combination demonstrated "high levels of clinical activity" in previously treated non-small cell lung cancer across a range of doses.
Anastrozole Shows Preventive Advantages Over Tamoxifen After DCIS
The first study to compare the efficacy and safety of tamoxifen versus anastrozole in women treated for ductal carcinoma in situ suggests that anastrozole may be the better choice for preventing the escalation of DCIS into invasive cancer.
First Effective Adjuvant Treatment Identified in High-Risk Prostate Cancer
Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.
Obinutuzumab Doubles PFS in Refractory Indolent Non-Hodgkin Lymphoma
Patients with relapsed indolent non-Hodgkin lymphoma experienced a doubling of progression-free survival when treated with a combination of the anti-CD20 agent obinutuzumab and bendamustine.
Novel JAK Inhibitor Alleviates Key Myelofibrosis Symptoms
Patients with myelofibrosis achieved significantly better outcomes in spleen volume reduction and symptom control with the novel JAK2 inhibitor pacritinib compared with best available therapy.
Daratumumab Data Impresses in Myeloma, FDA Submission Expected
Daratumumab demonstrated a 65% one-year overall survival rate and a 29.2% objective response rate in patients with double refractory heavily pretreated multiple myeloma.
Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study
Adding ibrutinib to standard bendamustine and rituximab (BR) reduced the risk of disease progression by 80% compared with BR plus placebo in patients with pretreated CLL or SLL.
Phase III Data Show Nivolumab Improves Survival Across Lung Cancer Subtypes
Nivolumab has now been shown to have an overall survival benefit versus docetaxel in both nonsquamous and squamous nonâ€“small cell lung cancer.
Study Opens Door for Nivolumab in HCC
Nivolumab generated antitumor responses in nearly 20% of patients with advanced HCC in a small study that suggests a promising role for the immunotherapy agent in a malignancy with dismal outcomes.
Pembrolizumab Demonstrates "Remarkable Efficacy" in Advanced HNSCC
In a multisite study offering the largest experience to date of how immunotherapy can be deployed in patients with head and neck cancer, the anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with advanced disease.
Mismatch Repair a Potential Biomarker for PD-1 Inhibition
Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.
2015 ASCO Annual Meeting Preview
Laura Jones provides a sneak peek at the top studies being presented at the 2015 ASCO Annual Meeting.
ASCO Offers Data Sharing to Help With Value Transition
PracticeNET is an initiative emerging from ASCO's Clinical Affairs Department designed to help practices learn from one another's successes as they move farther away from fee-for-service and toward increasingly cost-effective models of care.
ASCO Highlights Include Phase III Findings in Multiple Tumor Types
Findings from large, late-stage clinical trials in melanoma, nonâ€“small cell lung cancer, and several hematologic malignances are expected to rank among the most clinically significant research findings presented at the 2015 American Society of Clinical Oncology Annual Meeting.
Elotuzumab Combo Delays Myeloma Progression in Phase III Trial
Adding elotuzumab to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed/refractory multiple myeloma.
Large Study Adds Clarity to Use of Docetaxel With Standard Care in Advanced, Hormone-NaÃ¯ve Prostate Cancer
The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naÃ¯ve advanced prostate cancer.
Nicotinamide Reduces New Skin Cancers in Those at High Risk
For those with a history of non-melanoma skin cancer, reducing their risk of recurrence can be as simple as taking the vitamin B3 pill nicotinamide.
Intensified Chemotherapy Extends EFS for Children With Wilms Tumor
Treatment with an intensified chemotherapy regimen was associated with improvements in event-free survival for children with favorable histology Wilms tumor with loss of heterozygosity in chromosomes 1p and 16q.
FDA Approvals in Myeloma and ITP, Applications Accepted in Myeloma and More
Dr. Lee Highlights Key Takeaways From SPARTAN Trial in M0CRPC
Dr. Carlisle on Chemoimmunotherapy as Frontline Standard in Squamous NSCLC
Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer
Report Highlights Struggle to Help Survivors Prepare for Life After Treatment
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.